Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine
Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid
cancer to correlate the administered activity to absorbed dose. Patients will receive the
standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for
the protocol purpose.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
The primary outcome measure is to correlate the predicted dose from the tracer study with the actual absorbed dose measure on the therapeutic scan
Dr Kate Newbold
Principal Investigator
Royal Marsden NHS Foundation Trust
United Kingdom: Research Ethics Committee
CCR3047
NCT00749697
May 2008
July 2010
Name | Location |
---|